Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.

[1]  P. Sonneveld,et al.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Michael L. Wang,et al.  Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function. , 2006 .

[3]  J. Zeldis,et al.  A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma. , 2006 .

[4]  D. Ribatti,et al.  Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma , 2006, Oncogene.

[5]  Christian Jakob,et al.  Angiogenesis in multiple myeloma. , 2006, European journal of cancer.

[6]  Jason McCoy,et al.  Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Ribatti,et al.  Bone marrow angiogenesis in multiple myeloma , 2006, Leukemia.

[8]  P. Ravaud,et al.  High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Chauhan,et al.  Cytokines and signal transduction. , 2005, Best practice & research. Clinical haematology.

[10]  J. S. San Miguel,et al.  High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. , 2005, Blood.

[11]  G. Tricot,et al.  Immunomodulatory drugs in multiple myeloma , 2005, Expert opinion on investigational drugs.

[12]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[13]  K. Podar,et al.  The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. , 2005, Blood.

[14]  F. B. Sørensen,et al.  Syndecan‐1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival , 2005, British journal of haematology.

[15]  K. Zervas,et al.  The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro‐vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma , 2004, Hematological oncology.

[16]  M. Silva,et al.  Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma , 2004, European journal of haematology.

[17]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[18]  Santhosh K. P. Kumar,et al.  Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy , 2004, Bone Marrow Transplantation.

[19]  J. Esteve,et al.  Response to thalidomide in multiple myeloma: impact of angiogenic factors. , 2004, Cytokine.

[20]  Y. Ikeda,et al.  Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment , 2004, Pathology international.

[21]  Santhosh K. P. Kumar,et al.  Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma , 2004, Leukemia.

[22]  R. Fonseca,et al.  Plasma levels of tumour necrosis factor alpha and interleukin‐6 predict progression‐free survival following thalidomide therapy in patients with previously untreated multiple myeloma , 2003, British journal of haematology.

[23]  D. Ribatti,et al.  Vascular endothelial growth factor and its receptors in multiple myeloma , 2003, Leukemia.

[24]  G. Morgan,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[25]  W. Berdel,et al.  Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. , 2003, Blood.

[26]  D. Kyriakou,et al.  Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activity , 2003, American journal of hematology.

[27]  R. Fonseca,et al.  Prognostic value of angiogenesis in solitary bone plasmacytoma. , 2003, Blood.

[28]  J. Cavenagh,et al.  Thalidomide in multiple myeloma: current status and future prospects , 2003, British journal of haematology.

[29]  R. Fonseca,et al.  Bone marrow angiogenesis in multiple myeloma: effect of therapy , 2002, British journal of haematology.

[30]  Sung-Bae Kim,et al.  Comparison of Microvessel Density Before and after Peripheral Blood Stem Cell Transplantation in Multiple Myeloma Patients and Its Clinical Implications: Multicenter Trial , 2002, International journal of hematology.

[31]  R. Fonseca,et al.  Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  P. Hahnfeldt,et al.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.

[33]  A. Ogata,et al.  Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma , 2002, British journal of haematology.

[34]  J. Folkman,et al.  Angiogenesis-dependent diseases. , 2001, Seminars in oncology.

[35]  H. Goldschmidt,et al.  Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion , 2001, British journal of haematology.

[36]  S. Rajkumar,et al.  Angiogenesis in multiple myeloma. , 2001, Seminars in oncology.

[37]  N. Munshi,et al.  Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. , 2001, Seminars in oncology.

[38]  P. Brousset,et al.  Increased vascularization in myeloma. , 2001 .

[39]  K. Wernecke,et al.  Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma , 2001, European journal of haematology.

[40]  H. Goldschmidt,et al.  High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  M. Dietel,et al.  Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma , 2000, Annals of Hematology.

[42]  R. Fonseca,et al.  Prognostic value of bone marrow angiogenesis in multiple myeloma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  W. Berdel,et al.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. , 2000, Blood.

[44]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[45]  N. Raje,et al.  Thalidomide--a revival story. , 1999, The New England journal of medicine.

[46]  D. Ribatti,et al.  Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. , 1999, Blood.

[47]  T. Grogan,et al.  Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. , 1999, Cancer research.

[48]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[49]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[50]  B. Klein,et al.  Interleukin-6 in human multiple myeloma. , 1995, Blood.

[51]  A. Waage,et al.  TNF and IL‐6 are potent growth factors for OH‐2, a novel human myeloma cell line , 1994, European journal of haematology.

[52]  D. Ribatti,et al.  Bone marrow angiogenesis and progression in multiple myeloma , 1994, British journal of haematology.

[53]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[54]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[55]  Shaji K. Kumar,et al.  Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. , 2006, Haematologica.

[56]  D. Ribatti,et al.  Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. , 2006, Cancer research.

[57]  J. Esteve,et al.  Extramedullary multiple myeloma escapes the effect of thalidomide. , 2004, Haematologica.

[58]  P. Richardson,et al.  Thalidomide: emerging role in cancer medicine. , 2002, Annual review of medicine.

[59]  Mike Clarke,et al.  Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.